|
Patient characteristics
| |
n = 35
|
|---|
|
Sex
| |
male;28 : female;7 (80 %:20 %)
|
|
Age
| |
65.7 ± 5.7
|
|
Performance status (ECOG)
|
0
|
3 (8.6 %)
|
|
1
|
32 (91.4 %)
|
|
Histology
|
Small cell carcinoma
|
17 (48.6 %)
|
|
Adenocarcinoma
|
12 (34.3 %)a
|
|
Squamous carcinoma
|
3 (8.6 %)
|
|
Pleural mesothelioma
|
2 (5.7 %)
|
|
Large cell carcinoma
|
1 (2.9 %)
|
|
Clinical stage (UICC TNM)
|
I B
|
1 (2.9 %)
|
|
IIA
|
2 (5.7 %)
|
|
IIB
|
1 (2.9 %)
|
|
IIIA
|
6 (17.1 %)
|
|
IIIB
|
3 (8.6 %)
|
|
IV
|
21 (60.0 %)
|
|
Unknown
|
1 (2.9 %)
|
|
Smoking status
|
Never
|
6 (17.1 %)
|
|
Ever
|
11 (31.4 %)
|
|
Current
|
18 (51.4 %)
|
|
CDDP dosage (mg/m2)
| |
69.7 ± 8.9
|
|
CDDP cumulative dosage (mg/m2)
| |
278.6 ± 63.3
|
|
Course
| |
4.1 ± 0.9
|
|
CDDP dose reduction (%)
|
None
|
21 (60 %)
|
|
1 stage reduction
|
8 (23 %)
|
|
2 stage reduction
|
6 (17 %)
|
|
Regimen
|
CDDP + MTA ± BV
|
12 (34 %)
|
|
CDDP + VP-16
|
12 (34 %)
|
|
CDDP + CPT-11
|
5 (14 %)
|
|
CDDP + GEM
|
5 (14 %)
|
|
CDDP + DTX
|
1 (4 %)
|
|
Hydration volume (mL)
|
1937 ± 193
|
|
Infusion time (hr)
|
4.8 ± 1.1
|
|
Renal function
|
sCre (mg/dL)
|
0.7 ± 0.1
|
|
BUN (mg/dL)
|
14.3 ± 3.8
|
|
Adjusted eGFR (mL/min)
|
79.8 ± 9.9
|
- mean ± SD
-
a Driver mutation status; Epidermal Growth Factor Receptor; EGFR (+); n = 2, Anaplastic lymphoma kinase; ALK (+); n = 1
